Advances and Application of a Novel Oral Anticoagulant in Specific Populations: Dabigatran Etexilate

(E-pub Ahead of Print)

Author(s): Delai Xu*, Cujin Su, Jie Pan.

Journal Name: Current Drug Metabolism


Dabigatran Etexilate (DE) was approved by the FDA in 2010 to reduce the risk of stroke and systemic embolism in adults with Non-valvular Atrial Fibrillation (NVAF). Compared with warfarin, a traditional anticoagulant drug, DE exhibits a shorter half-life, improved dose-effect relationship, fewer food and drug interactions, and can be taken orally without monitoring the conventional coagulation index. DE can also prevent or reduce the severity of adverse events, such as attenuated drug efficacy or bleeding. It is convenient for patients to take DE due to low levels of individual variation. We review the pharmacological mechanisms, pharmacokinetics and drug interactions, as well as the application of DE for different clinical populations, and provide clinical guidelines.

Keywords: Dabigatran etexilate, Novel oral anticoagulants, pharmacokinetics, drug interactions, specific populations.

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1389200219666181011160133
Price: $95

Article Metrics

PDF: 21